Gde-based CRISPR nuclease detection platform for RNA and DNA analysis
A novel CRISPR nuclease (G-dase E) with collateral cleavage activity enables specific nucleic acid detection through lateral flow or fluorometric readouts. The platform supports point-of-care diagnostics, SNP and insertion detection in plants, and integration with isothermal amplification for low-concentration targets.
Overview
This offering centers on G-dase E (GDE), a novel CRISPR nuclease that, once guided by a gRNA to a specific RNA target, performs collateral cleavage of surrounding DNA and RNA in a non-specific manner. This unique mode of action is harnessed to hydrolyze labeled DNA detector molecules upon target binding, producing a visible or fluorescent signal. The platform supports both lateral flow assays for rapid, easy field readouts and fluorometric assays for sensitive, quantitative detection. It is designed for one- or two-pot reactions and can be integrated with a lab-on-a-chip device for point-of-care use. Applications include viral subtyping, plant genotyping (SNPs and insertions), and detection of low-abundance nucleic acids when paired with isothermal amplification.
Technical specifications
Key features:
- Programmable specificity: gRNA directs GDE to a chosen RNA target sequence, triggering collateral cleavage only when the match is present
- Dual readout formats: lateral flow strip assay for fast qualitative results; fluorometric assay for quantitative measurement
- Crude extraction compatibility: nucleic acids can be isolated by simple crude extraction suitable for field conditions
- Amplification-ready: can be combined with reverse transcriptase, recombinase polymerase amplification (RPA), and RNA-polymerase for low-concentration targets
- Flexible reaction setup: one- or two-pot reaction formats simplify workflow
- Broad target range: validated for viral RNA subtypes, plant RNA SNPs and insertions, and DNA detection via RNA-polymerase coupling
- Lab-on-a-chip potential: designed for integration into miniaturized devices for rapid amplification and detection
Workflow:
- Crude RNA/DNA extraction and dilution
- Isothermal RT-RPA (optional, for low-concentration targets)
- GDE activation
- Lateral flow or fluorometric readout
Technology readiness level
The technology has been validated in proof-of-concept studies demonstrating subtype-specific activation of GDE using different gRNAs against viral RNA targets. Both lateral flow and fluorometric assay formats have shown successful detection of viral subtypes as well as SNPs and insertions within plant RNA. DNA detection has also been demonstrated by combining the assay with an RNA-polymerase. Next steps include developing a crude extraction method compatible with GDE activity, determining minimum detection thresholds across target sites, and establishing one- or two-pot reactions with isothermal amplification. The team is actively seeking a partnership to co-develop a lab-on-a-chip device for integrated amplification and detection.
About Akribion Genomics
Akribion Genomics, which operates under the legal entity Akribion Therapeutics, is a biotechnology company developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion. Using its proprietary G-dase® E payload, the company's platform works by shredding DNA and RNA only when a highly specific match occurs between a guide RNA and an intracellular RNA sequence. This mechanism allows for precise differentiation between targeted and healthy cells, offering a modular and flexible approach where new targets can be addressed simply by exchanging the guide RNA. Originally spun out of BRAIN Biotech AG, the company leverages this nuclease technology to innovate in the field of precision oncology and beyond.
The technology is primarily aimed at addressing significant medical needs, with an initial focus on HPV-induced Oropharyngeal Head & Neck Cancer (OPSCC). By providing a highly specific and adaptable platform, Akribion aims to develop faster, more effective therapeutic alternatives compared to traditional methods. Beyond oncology, the company is actively exploring applications in autoimmune diseases, fibrosis, and infectious diseases. Supported by institutional venture financing, the company works to advance these novel therapeutics while maintaining a commitment to high ethical standards in the development of its CRISPR-based genome editing tools and genetic medicine solutions.
delivered to your inbox.